title: New biological treatments for psoriatic arthritis.
authors.forename: Piercarlo
authors.initials: P
authors.lastname: Sarzi-Puttini
authors.forename: Fabiola
authors.initials: F
authors.lastname: Atzeni
mesh_terms: D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000145:classification / Q000627:therapeutic use; D015535:Arthritis, Psoriatic / Q000188:drug therapy / Q000276:immunology; D002986:Clinical Trials as Topic; D006801:Humans; D007155:Immunologic Factors / Q000145:classification / Q000627:therapeutic use; D020381:Interleukin-17 / Q000037:antagonists & inhibitors*; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D017063:Outcome Assessment, Health Care; D000069283:Rituximab; D013792:Thalidomide / Q000031:analogs & derivatives / Q000627:therapeutic use; D000079424:Tumor Necrosis Factor Inhibitors; D000069549:Ustekinumab
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D007155:Immunologic Factors; D020381:Interleukin-17; D000079424:Tumor Necrosis Factor Inhibitors; D000069283:Rituximab; D013792:Thalidomide; D000069549:Ustekinumab; C505730:apremilast; D008727:Methotrexate